Bronchopulmonary Dysplasia - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 49 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Bronchopulmonary Dysplasia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Bronchopulmonary Dysplasia - Pipeline Review, H2 2014', provides an overview of the Bronchopulmonary Dysplasia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bronchopulmonary Dysplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchopulmonary Dysplasia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bronchopulmonary Dysplasia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bronchopulmonary Dysplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bronchopulmonary Dysplasia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bronchopulmonary Dysplasia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bronchopulmonary Dysplasia Overview 6
Therapeutics Development 7
Pipeline Products for Bronchopulmonary Dysplasia - Overview 7
Pipeline Products for Bronchopulmonary Dysplasia - Comparative Analysis 8
Bronchopulmonary Dysplasia - Therapeutics under Development by Companies 9
Bronchopulmonary Dysplasia - Therapeutics under Investigation by Universities/Institutes 10
Bronchopulmonary Dysplasia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Bronchopulmonary Dysplasia - Products under Development by Companies 14
Bronchopulmonary Dysplasia - Products under Investigation by Universities/Institutes 15
Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development 16
MediPost Co., Ltd. 16
Syntrix Biosystems, Inc. 17
Ikaria Inc. 18
Clarassance, Inc. 19
Bronchopulmonary Dysplasia - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Inomax - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Pneumostem - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CG-100 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Inhibit RAR-Gamma for Emphysema and Bronchopulmonary Dysplasia - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
SX-682 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
R-190 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
R-908 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Bronchopulmonary Dysplasia - Recent Pipeline Updates 40
Bronchopulmonary Dysplasia - Dormant Projects 41
Bronchopulmonary Dysplasia - Discontinued Products 42
Bronchopulmonary Dysplasia - Product Development Milestones 43
Featured News & Press Releases 43
Feb 06, 2014: Stem cells to treat lung disease in preterm infants 43
Dec 04, 2012: Discovery Labs Announces Presentation Of Surfaxin Pharmacoeconomic Analysis Data At 2012 Hot Topics In Neonatology Annual Meeting 43
Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem 45
May 31, 2012: Medipost Submits Application To KFDA For Pneumostem Clinical Trial 45
Feb 27, 2012: Ikaria Completes Patient Enrollment In Pivotal Phase III Trial For Bronchopulmonary Dysplasia 46
Jan 05, 2011: Ikaria Receives Marketing Exclusivity Extension For Inomax From FDA 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products under Development for Bronchopulmonary Dysplasia, H2 2014 7
Number of Products under Development for Bronchopulmonary Dysplasia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Bronchopulmonary Dysplasia - Pipeline by MediPost Co., Ltd., H2 2014 16
Bronchopulmonary Dysplasia - Pipeline by Syntrix Biosystems, Inc., H2 2014 17
Bronchopulmonary Dysplasia - Pipeline by Ikaria Inc., H2 2014 18
Bronchopulmonary Dysplasia - Pipeline by Clarassance, Inc., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Bronchopulmonary Dysplasia Therapeutics - Recent Pipeline Updates, H2 2014 40
Bronchopulmonary Dysplasia - Dormant Projects, H2 2014 41
Bronchopulmonary Dysplasia - Discontinued Products, H2 2014 42